Aagaard, Nikolaj
Olsen, Markus Harboe
Rasmussen, Oliver Wiik
Grønbaek, Katja K.
Mølgaard, Jesper
Haahr-Raunkjaer, Camilla
Elvekjaer, Mikkel
Aasvang, Eske K.
Meyhoff, Christian S.
Funding for this research was provided by:
Novo Nordisk Fonden (NNF21SA0069370)
Copenhagen University
Article History
Received: 6 March 2024
Accepted: 4 July 2024
First Online: 20 August 2024
Declarations
:
: Christian S. Meyhoff and Eske K. Aasvang have founded a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project. WARD247 ApS has obtained license agreement for any WARD-project software and patents. One patent has been filed: “Wireless Assessment of Respiratory and circulatory Distress (WARD) – Clinical Support System (CSS) – an automated clinical support system to improve patient safety and outcomes”. Eske K. Aasvang reports advisory board work with GenEdit and Concentric Analgesics. Katja Kjær Grønbæk are employed as head of clinical affairs in the start-up company WARD 247 ApS. Oliver Wiik Rasmussen are employed as a data scientist in the start-up company WARD 247. None of the above entities have influence on the study design, conduct, analysis, or reporting. The remaining authors declare no conflicts of interest.